发现了伊塔科纳酸和衍生品的口服产药
Chae Bin Lee, Ivan Šnajdr1, Lukáš Tenora1
1Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic v.v.i., Prague 160 00, Czech Republic.
新的口服可用的伊塔康酸原药克服了细胞透性差. 基于POC的衍生品P2和P13通过提高itaconate的生物可用性,显示出治疗炎症性皮肤和全身疾病的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 伊塔科纳酸是一种三碳酸 (TCA) 循环代谢物,是一种具有治疗潜力的内源性免疫调节剂.
- 它的高极性和较差的细胞透性限制了临床应用.
- 之前的工作确立了局部伊塔科纳酸衍生物用于白发症.
研究的目的:
- 为了发现口服可用的伊塔科纳酸衍生物用于全身和皮肤疾病.
- 通过前药物策略来增强伊塔科纳酸的细胞透性和口服生物利用性.
主要方法:
- 使用POM,POC,ODOL和HDP原剂合成四组伊塔科纳酸原药.
- 对前药物稳定性,透性和药理动学的评估.
- 对人类表皮皮质角质细胞的抗炎作用的评估.
- 在体内进行的口服药理动力学研究.
主要成果:
- 基于POC的前药物 (P2,P9,P13) 显示出有利的稳定性,透性和药理动力学.
- P2和P13显著抑制了Poly (I:C) /IFNγ诱导的炎症性细胞因子.
- 口服P2和P13导致了有利的药理动力学,释放伊塔康酸 (IA) 或4-甲基伊塔康酸 (4-MI).
结论:
- 前药物策略可以有效地改善itaconate的细胞透性和口服生物可用性.
- 开发的伊塔科纳酸原药显示出治疗炎症性皮肤和系统性疾病的潜力.
- 这些发现支持基于伊塔康酸盐的治疗方法的临床转化.
更多相关视频
08:36Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Prodrugs
Prodrugs help overcome...
Drug Discovery: Overview
Methods for Studying Drug Absorption: In situ
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
Drug Delivery: Enteral Route
Drug Metabolism: Phase II Reactions
Drugs for Treatment of Constipation-Predominant IBS
![Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F59557.jpg&w=3840&q=50)